The Impact of a 48-hour Fast with or Without Exercise on Immune Cell Metabolism and Glycemic Control in Healthy Active Adults

NCT ID: NCT06737224

Last Updated: 2025-03-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-10

Study Completion Date

2025-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many individuals engage in fasting for its purported health benefits but the effects of fasting on immune cell and whole body metabolism are not well understood in humans. Moreover, how exercising during a prolonged fast impacts immunometabolic outcomes is unclear. This study will determine how a 2 day fast - performed with or without daily exercise - impacts immune cell bioenergetics, immune cell function, and whole-body glycemic control in healthy active individuals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will perform two, 48-hour fasts separated by 5 days while wearing a continuous glucose monitor to measure glycemic responses. The order of the trials will be randomized for each participant. The two trials will include an exercise condition (FAST+EX) and a control, non-exercise condition (FAST). During the FAST+EX trial, participants will perform 60 minutes of cycling on each of the two days of the fast. Each bout of exercise will be 60 minutes in duration and consist of 50 minutes of cycling at 60% of predicted heart rate reserve (HRR) followed by 5 x 1-minute intervals at 90% of predicted HRR with 1-minute of passive recovery between each interval. During the FAST trial, participants will be asked to refrain from any structured exercise during the days of the fast. To start the trial, participants will arrive at the lab following an overnight fast. They will consume a standardized meal replacement (Ensure Plus Calories) and blood will be drawn 2 hours post-ingestion. Participants will come to the lab 24 and 48 hours later for subsequent blood draws prior to breaking their fast with the same standardized meal replacement. Another blood sample will be taken 2 hours post-prandial. Participants will be asked to replicate food consumption in each condition for the 24-hour period after they break their fast, and consume the same standardized meal replacement on the morning following the completion of each fast to measure free-living glycemic control 24-hours after a fast performed with or without exercise. There will be a five-day wash out period in between the completion of both trials for all participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fasting Immune Function Glucose Tolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized crossover, within-subject, repeated measures
Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fasting + Exercise (FAST+EX): fasting + exercise condition

48-hour fast with 60 minutes of cycling on the first and second day of the fast.

Group Type EXPERIMENTAL

Fasting + Exercise (FAST+EX): fasting + exercise condition

Intervention Type OTHER

Participants will complete a 48-hour fast. One hour of exercise will be performed on each morning of the fast.

Fasting only (FAST): Non-exercise fasting condition

48-hour fast with no structured exercise on fasting days.

Group Type EXPERIMENTAL

Fasting only (FAST): Non-exercise fasting condition

Intervention Type OTHER

Participant will complete a 48-hour fast. No structured exercise will be performed during each of the fasting days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fasting + Exercise (FAST+EX): fasting + exercise condition

Participants will complete a 48-hour fast. One hour of exercise will be performed on each morning of the fast.

Intervention Type OTHER

Fasting only (FAST): Non-exercise fasting condition

Participant will complete a 48-hour fast. No structured exercise will be performed during each of the fasting days.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 19 and 35 years.
* Physically active (engaging in ≥150 minutes of weekly moderate to vigorous physical activity).

Exclusion Criteria

* History of cardiometabolic diseases or inflammatory diseases (e.g., chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, cardiovascular disease).
* Individuals currently following a ketogenic diet, low-calorie diet, periodic fasting regimen, or consuming ketogenic supplements (e.g., exogenous ketone drinks).
* Cigarette/vaping smoking.
* Physical limitation that will impair the ability of the participant to perform exercise.
* Individuals having a body mass index (BMI) over 30 kg/m2.
* Cancer diagnosis in the past 5 years.
* Taking anti-inflammatory drugs (e.g., ibuprofen, aspirin, naproxen).
* Being unable to read or communicate in English.
Minimum Eligible Age

19 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of British Columbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jonathan Little

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of British Columbia Okanagan Campus

Kelowna, British Columbia, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jonathan Little Principal Investigator, Professor Little, Ph.D

Role: CONTACT

250-807-9876

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alexis Marcotte-Chénard Postdoctoral fellow, Ph.D

Role: primary

250-807-9876

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H24-01732

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Redox Status and Immune Function
NCT02930031 COMPLETED NA
Researching Economical Adjuvants to Cancer Therapy
NCT07305259 RECRUITING EARLY_PHASE1